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The endothelin pathway: a protective or detrimental target of bardoxolone methyl
on cardiac function in patients with advanced chronic kidney disease?
Abstract
Bardoxolone methyl has been reported to cause detrimental cardiovascular events in the terminated
BEACON Phase III human clinical trial via modulation of the renal endothelin pathway. However, the
effects of bardoxolone methyl administration on the endothelin pathway in the heart are unknown. Our
purpose in this perspective is to highlight the distinctive opposing roles of the renal and heart endothelin
pathway in cardiac function. Furthermore, we address the need for further investigation in order to
determine if bardoxolone methyl has a protective role in cardiac function through the suppression of the
endothelin pathway in the heart.
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The endothelin pathway: a protective or detrimental target of bardoxolone methyl on
cardiac function in patients with advanced chronic kidney disease?
The paradoxical nature of Bardoxolone methyl (BM) has been widely noted in recent
scientific literature (Van Laecke, Van Biesen et al. 2014). There are many known antiinflammatory and anti-oxidative properties of this drug that have shown promise in
preclinical studies, including treating complications of diabetes such as retinopathy and
nephropathy (Camer, Yu et al. 2014). In addition, phases 1 and II of human clinical trials in
patients with chronic kidney disease found that BM markedly improved kidney function
(Pergola, Krauth et al. 2011; Pergola, Raskin et al. 2011). These positive results from the
earlier phases led to the BEACON phase III human clinical trial in patients with type 2
diabetes and stage 4 chronic kidney disease (de Zeeuw, Akizawa et al. 2013). However, this
trial was terminated due to safety concerns centred on an increased incidence of
cardiovascular events in BM treated patients compared to the placebo group (de Zeeuw,
Akizawa et al. 2013). This has lead to scepticism in the scientific community as to whether
BM will ever be used in the future treatment of diseases such as chronic kidney disease.
The mechanisms contributing to the adverse cardiovascular events seen in patients treated
with BM in the BEACON trial have since been addressed (Chin, Reisman et al. 2014). It was
concluded that the modulation of the endothelin pathway provided an explanation of the
mechanisms by which BM caused an increase in cardiovascular events in participants. It was
also found that BM was able to suppress the endothelin pathway in the kidneys of chronic
kidney disease (CKD) induced rodents and healthy cynomolgus monkeys by reducing the
protein expression of the ETA receptor (Chin, Reisman et al. 2014). In healthy cynomolgus
monkeys, BM did not affect ETB receptor expression (Chin, Reisman et al. 2014). However,
in rodents induced with CKD, BM restored ETB receptor levels to those observed in the
control animals(Chin, Reisman et al. 2014). Thus these results are extremely important in
trying to explain the detrimental cardiovascular events that occurred in a number of patients
taking BM in this human clinical trial. Despite this, there are limitations in the creation of this
conclusion, since only the endothelin pathway of kidney tissue and not also cardiac tissue
was examined.
It is well established that renal endothelin 1 (ET-1) has several important functions including
regulating sodium and water homeostasis, renal blood flow and acid base balance via
activation of ETA and ETB receptors(Kohan 2006) (Table 1). Furthermore, if the endothelin
system is suppressed, such as from being targeted by BM, this balance is disturbed causing
fluid retention, which can lead to heart failure(Kohan 2006). However, it is important to note
that the endothelin pathway in the heart has a different function to the kidneys. ET-1 in the
cardiac muscle promotes cardiac hypertrophy and subsequent heart failure via activation of
ETA receptors(Nasser and El-Mas 2014) (Table 1). Furthermore, both ETA receptor and
combined ETA/ETB receptor antagonism has been shown to lower blood pressure, and reduce
infarct size in patients with congestive heart failure (Nasser and El-Mas 2014). Thus,
suppressing the endothelin pathway in the heart would be protective against adverse
cardiovascular vascular events.

In our opinion, due to the differing functions of the endothelin pathway in the kidneys and
heart, we feel that more evidence is required to conclude that BM treatment caused adverse
cardiovascular events by suppression of the renal endothelin pathway. Future investigation of
the effects of BM on cardiac tissue is required in order to determine if BM inhibits ETA
receptors in the heart causing its protection.
Table 1 Summary of endothelin system functions in the kidney and vascular system
Kidneys

Vascular System

ET-1
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sodium Vasoconstrictor and
and
water sodium
retention
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effects

Regulates vascular Vasoconstrictor
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cardiac (smooth muscle)
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ETB receptors
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and
sodium
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vasopressin activity
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